Navigation Links
Elevation Pharmaceuticals Strengthens Management Team with Appointment of Executives
Date:9/26/2011

SAN DIEGO, Sept. 26, 2011 /PRNewswire/ -- Elevation Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, today announced the appointment of Jaisim Shah as Senior Vice President and Chief Business Officer and Pravin Soni, PhD, as Senior Vice President and Chief Technical Officer, both newly created positions. The company also announced that it drew down $17 million from its tranched Series A financing, triggered by positive Phase 2a clinical trial results of its lead product, EP-101, for the treatment of chronic obstructive pulmonary disease. The second part of the financing will help fund an ongoing Phase 2b clinical trial of EP-101 for which data is expected by the end of the first quarter 2012.

"Mr. Shah and Dr. Soni bring strong commercial and technical leadership skills to Elevation," stated Bill Gerhart, President and CEO of Elevation.  "Their addition to the Elevation leadership team significantly enhances our ability to develop and optimally position in the marketplace new inhaled drug therapies that meet significant unmet clinical needs."

Mr. Shah is a senior-level commercial and business development executive with 27 years of experience in business development, commercial operations, investor relations, marketing and medical affairs, including leadership positions at F. Hoffman-LaRoche, Bristol-Myers Squibb and PDL BioPharma.  At Elevation, Mr. Shah will be responsible for all product positioning and business development activities.  Prior to Elevation he was President of Zelos Therapeutics, where he focused on financing and business development. Prior to Zelos, he was the Senior Vice President and Chief Business Officer at CytRx, a biopharmaceutical company.  Prior to CytRx, Mr. Shah was Chief Business Officer at Facet Biotech and PDL BioPharma where he completed numerous licensing/partnering and strategic transactions with pharmaceutical and biotech companies. Prior to PDL he was at Bristol-Myers Squibb, most recently as Vice President of Global Marketing where he received the "President's Award" for completing one of the most significant collaborations in the company's history. Prior to working for Bristol-Myers Squibb, Mr. Shah was at F. Hoffman-La Roche in international marketing and was global business leader for corporate alliances with Genentech and Idec. He holds an MA in Economics from the University of Akron and an MBA from the University of Oklahoma and serves on the Board of Directors at Acucela.

"Considering the positive Phase 2a trial results announced today and the draw-down of the $17 million tranche of its Series A financing, Elevation is poised to accelerate the development of its lead candidate and begin development of its pipeline," said Jaisim Shah. "I am very pleased to be joining the Company at this exciting stage, and I look forward to working with the rest of the management team to help realize Elevation's full potential."

Dr. Soni has more than 30 years of experience developing products in a range of industries, including 17 years in senior management leading the development, manufacture and registration of novel drug, device and combination medical products. At Elevation, Dr. Soni will be responsible for all device and drug development activities.  Prior to Elevation, he was Vice President of Product Research and Development at Alexza Pharmaceuticals where he led the development of a novel inhalable drug delivery system, the Staccato® inhaler, for systemic drug delivery via the deep lung. Five different drug candidates based on Staccato technology intended for the treatment of migraine, panic attack, breakthrough pain, insomnia and agitation are currently in various stages of clinical evaluation. Prior to Alexza, Dr. Soni was Vice President of Engineering at Cygnus where he led the development of the first commercial non-invasive, automatic, and continuous blood glucose monitoring system, the GlucoWatch Biographer, as well as a seven-day contraceptive transdermal system that was marketed by Johnson & Johnson as Evra®. Before Cygnus, Dr. Soni spent 15 years at Raychem Corporation developing novel products based on specialty materials. Dr. Soni is a co-inventor on 57 US and foreign patents and has co-authored 19 publications/poster presentations. He holds a PhD in Macromolecular Science and Engineering from Case Western Reserve University.

About Elevation Pharmaceuticals

Elevation Pharmaceuticals is a biopharmaceutical company focused on developing new inhaled therapies for patients with respiratory disease. The Company's initial focus is on developing novel therapies for the underserved subpopulation of COPD patients not able to effectively control their disease with dry powder or metered dose inhalers.  Elevation's lead drug candidate is EP-101, an inhalation solution formulation of glycopyrrolate, a long-acting muscarinic antagonist bronchodilator, in Phase 2 studies for the improved treatment of patients with severe COPD.  Elevation is a privately held company headquartered in San Diego, California. For additional information, please visit www.elevationpharma.com


'/>"/>
SOURCE Elevation Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Volcano Corporation Commends the Elevation of FFR to Level of Evidence A in New PCI Guidelines
2. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
3. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
4. Valeant Pharmaceuticals Intends to Raise Offer for Afexa Life Sciences Inc. to $0.85 per Share
5. Clermont Pharmaceuticals Reports Positive Phase III Results for Drug to Treat Glaucoma
6. Pacira Pharmaceuticals, Inc. Announces Efficacy and Safety of EXPAREL™ Highlighted at "Hot Topics in Plastic Surgery" Panel at the 2011 Annual Meeting of the American Society of Plastic Surgeons
7. Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products
8. Zacks Industry Outlook Highlights: Vertex Pharma, AstraZeneca, Abbott Labs, Allergan and Onyx Pharmaceuticals
9. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
10. Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma
11. Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... N.J. , Feb. 9, 2016  Bluestar Silicones ... (LSR) product line for long-term implant applications and ... Medical Design & Manufacturing (MD&M) West Conference (Booth ... --> --> ... Silbione® Biomedical LSRs offer outstanding physical properties enabling ...
(Date:2/8/2016)... , Feb.8, 2016 Respiratory Devices - ... GlobalData,s Medical Devices sector report, " Respiratory Devices ... an overview of Respiratory Devices currently in pipeline ... the pipeline products with comparative analysis of the ... reviews major players involved in the pipeline product ...
(Date:2/8/2016)... , Feb. 8, 2016 CBG Technologies, ... PW Series Solvent Recycling Systems, specifically designed for ... integration with new and existing vapor degreasers, parts ... consistently-fresh solvent through continuous recycling and recovers 100% ... --> --> Precision parts manufacturers ...
Breaking Medicine Technology:
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... On January ... family scheduled an appointment after they noticed their furnace not producing any heat. Shortly ... heat exchanger. The cracked heat exchanger was leaking dangerous levels of carbon monoxide into ...
(Date:2/9/2016)... ... ... METTLER TOLEDO has published a new guide entitled “Essential ... the techniques they use so they can more easily spot potential error sources ... to create a leaner overall lab experience. , The new guide offers ...
(Date:2/9/2016)... ... ... i2i Systems, an early innovator and developer of population health management technology, ... report, Population Health Management 2015: How Far Can Your Vendor Take You? , ... The latest KLAS Report, leveraging over 200 user interviews, shines a light on ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... Nutrition into the Food & Beverage and Dietary Supplement ... partner throughout Canada and USA geographies east of the Rocky Mountains since 2012. ...
(Date:2/8/2016)... ... February 08, 2016 , ... Brenton ... for pouches, bags, and flow wrapped products at WestPack 2015, February 9-11, in ... manufacturers step up to semi-automatic or fully-automatic case packing with a small footprint, ...
Breaking Medicine News(10 mins):